Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

The company also recently earned regulatory approval in the U.S. for mFLUSIVA, an influenza vaccine, a niche where it should ...

Moderna MRNA recently secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine. The decision is a ...

Moderna (MRNA) stock climbed 3.6% on melanoma vaccine trial success and COVID approval, but analysts remain cautious with $80 ...

Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher.

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free ...

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and ...

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares?

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...